AlphAIAlphAI — Financial news for AI agents
marketscreener.comSEP 71 min read

Anteris Technologies Global Corp. Announces CFO Changes, Effective September 11, 2026

Anteris Technologies Global Corp. announced Brent Moen as its new CFO, effective September 11, 2026. Moen has over 25 years of experience, including roles at LifeLens Technologies and Tactile Systems Technology. Matthew McDonnell will step down as CFO on the same day.

Original reporting
marketscreener.com
Published Sep 7, 2026, 8:51 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 7, 2026, 8:52 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefCorporate actions
Primary signal
MARKET
Neutral
AI market analysis
Mentioned
$AVR
Relevance
7/10
AlphAI data visualization · based on marketscreener.com
Decision brief

The 30-second read

Low
01

Why it matters

The CFO appointment is a standard corporate action with limited immediate price impact.

02

Market read

Executive change may affect investor perception but unlikely to move the stock significantly.

03

What to watch

Potential hidden strategic initiatives tied to the CFO's prior experience in med‑tech.

Relevance 7/10Novelty 7/10Timing: effective Sep 11 2026

Background

Anteris Technologies Global Corp. is a medical‑technology company listed on NASDAQ.

Market effects

Sector

Minor for medical technology sector; no immediate sector‑wide impact.

Regional

U.S. market only; no broader regional effect.

Global

Low global relevance.

Counterpoint

What could challenge this read

If the new CFO drives aggressive M&A, the stock could rally.

Key entities

  • Person
    Brent Moen

    New Chief Financial Officer.

  • Person
    Matthew McDonnell

    Outgoing Chief Financial Officer.

Read at source← All news

Related articles

AUG 12
$AVRMed

Anteris Advances DurAVR Toward Commercialization; PARADIGM Trial Expands U.S. Recruitment

Anteris Technologies Global Corp. (AVR) reported Q2 2026 results and said it secured U.S. Medicare reimbursement eligibility for PARADIGM Trial procedures. The company began U.S. recruitment, with first patients treated in May 2026, and said the trial is recruiting in the U.S., Denmark and the Netherlands. Net operating cash outflow was $20.8M; R&D expense was $23.4M.

rttnews.com5 min
AUG 12
$AVRMed

Anteris Technologies advances PARADIGM Trial in June quarter as US patient recruitment gets underway

Anteris Technologies (ASX:AVR, NASDAQ:AVR) said it advanced its pivotal PARADIGM Trial in the June quarter, enrolling and treating its first US patients after CMS Medicare reimbursement eligibility for qualifying procedures. Recruitment expanded to the US, Denmark and the Netherlands, with Canada and France receiving regulatory clearance. The trial targets about 1,000 patients. Net operating cash outflows were US$20.8m.

proactiveinvestors.com.au4 min
AUG 11
$AVRMedAI 8/10

Anteris Technologies Announces Results for the Second Quarter of 2026

Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) reported Q2 2026 results for the quarter ended June 30, 2026. It said CMS granted Medicare reimbursement eligibility for the PARADIGM Trial, U.S. recruitment began with first patients treated in May 2026, and the trial expanded to multiple regions. Net operating cash outflows were $20.8M; R&D expenses were $23.4M.

leaderpost.com6 min
AUG 11
$AVRLow

Anteris Technologies Global Corp. (AVR): Results of Operations and Financial Condition

Anteris Technologies Global Corp. (AVR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Anteris Technologies Announces Results for the Second Quarter of 2026 MINNEAPOLIS, United States and BRISBANE, Australia August 12, 2026 (AEST) Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) a global healthcare company committe

SEC EDGAR 8-K4 min
JUN 4
$AVRMed

Anteris Technologies Global (NASDAQ:AVR) Shares Up 12.6% – Should You Buy?

Anteris Technologies Global (NASDAQ:AVR) shares rose 12.6% to $10.0750 on Thursday, after closing at $8.95; the stock traded between $9.71 and $10.0750. Volume was 176,960 shares, down 84% vs. average. Analysts cited mixed views: Barclays raised its target to $18 (overweight), while Wall Street Zen moved to hold; consensus target is $16. In its May 12 earnings, the company reported -$0.28 EPS vs -$0.27 expected on $0.49M revenue vs $0.77M.

tickerreport.com5 min